SMITHS-DETECTION
14.3.2023 08:02:09 CET | Business Wire | Press release
Smiths Detection, a global leader in threat detection and security screening technology, today announces the launch of its latest chemical agent identifier, Lightweight Chemical Detector (LCD) 4 alongside the LCD XID extension. This will expand the detection capabilities of the LCD to include street narcotics, explosives, pharmaceuticals, and other super toxic chemical threats.
The capability of LCD can be transformed by placing the detector into the XID cradle, where it immediately turns the vapour detection device into a ruggedised mobile trace detector that can be used in any CBRNe (Chemical, Biological, Radiological, Nuclear and Explosive) scenario.
The XID has been developed as a direct response to the request from existing LCD customers to adapt the capabilities of the detector to the constantly evolving global threat environment which is driving the requirement to detect and identify minute quantities of super toxic threats such as fentanyl and novichok.
The LCD series is the most widely deployed personal chemical detector globally, over 100,000 detectors are in service with operators in 58 different countries. The largest operator is the US DOD through its Joint Chemical Agent Detector (JCAD) Program. The LCD and LCD XID have been evaluated in the Organisation for the Prohibition of Chemical Weapons laboratories and provide the benchmark for personal protection against toxic chemical threats.
Smiths Detection’s Defence Market Director, Michael Lea, said: “The LCD 4 and the XID have been developed to respond to the changing threat environment. The XID gives CBRNe and HAZMAT operators the ability to detect and identify a far broader range of threats that they may encounter on everyday operations. The XID is a great illustration of Smiths Detection’s capability to develop products in response to customer needs and helping us to achieve our mission to make the world safer place.”
The LCD 4 & XID will be on display at the Security & Policing event in Farnborough, UK, 14-16 March (booth C87).
ABOUT SMITHS DETECTION:
Smiths Detection, a division of Smiths Group, is a global leader in inspection and detection technologies for the air transport, ports and borders, armed forces and urban security markets. With more than 70 years of experience in the field, we offer the necessary solutions to protect society from the threats posed by explosives, prohibited weapons, contraband, toxic chemical agents and narcotics – helping to make the world a safer place.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005150/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release
The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release
Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 12:00:00 CEST | Press release
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFSMANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusionsFull results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-
Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or
Global Database Launches Regis, an AI Assistant for Live Company Registry Data30.6.2026 11:13:00 CEST | Press release
Regis gives business users a ChatGPT-like experience for company research, compliance checks, ownership discovery, financial analysis, and prospect list building — powered by live data from official government registries Global Database today announced the launch of Regis, a new AI assistant designed to answer business questions using live company data from official government registries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630229011/en/ Unlike general-purpose AI tools that rely on training data or open web sources, Regis is connected to Global Database’s structured company intelligence platform, covering more than 600 million company profiles, sourced from over 400 government registries across more than 200 countries. For more than a decade, Global Database has been collecting, structuring, and maintaining company data directly from government registries around the world. With the launch of Regis, the company
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
